PE Anti-Human CD274 (PD-L1) Antibody

Product Details


CloneAtezolizumab
ApplicationFlow Cytometry
ReactivityHuman
FormatPE
Target NameCD274, PD-L1, B7-H1, Programmed cell death ligand 1, B7 homolog 1
IsotypeHuman IgG1
Antibody TypeMonoclonal
Regulatory StatusRUO
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA
Protein ConcentrationSupplied at a lot-specific concentration.
Storage & HandlingThe antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Recommended UsageFor flow cytometric staining, it is recommended to use 5 µL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. iF488 has an excitation max at 491 nm and an emission max at 516 nm.
Excitation LaserBlue Laser (488 nm) Green/Yellow laser (532/561nm)
See All FormatsClone Atezolizumab

Background Information


Human programmed death-ligand 1 (PD-L1), also known as CD274 or B7-H1, is an immune checkpoint protein that plays a central role in regulating T-cell activity and maintaining peripheral immune tolerance. PD-L1 is expressed on antigen-presenting cells, including dendritic cells and macrophages, and can be induced on many other cell types by inflammatory cytokines such as interferon-γ. It is frequently upregulated by tumor cells as a mechanism of immune evasion.



PD-L1 is a type I transmembrane glycoprotein of approximately 290 amino acids. Its extracellular region contains an N-terminal immunoglobulin variable (IgV)-like domain and a membrane-proximal IgC2-like domain, followed by a single transmembrane helix and a short cytoplasmic tail of approximately 30 amino acids. The IgV domain contains the primary binding interface for PD-1. Structural studies show that PD-L1 engages PD-1 through an extensive protein-protein interface involving hydrophobic and polar interactions.



The principal receptor for PD-L1 is programmed cell death protein 1 (PD-1/CD279), expressed mainly on activated T cells and other immune cells. PD-L1 can also interact with B7-1 (CD80), including interactions occurring in cis on antigen-presenting cells. Engagement of PD-1 by PD-L1 suppresses T-cell receptor signaling, proliferation, cytokine production, and cytotoxic activity, thereby limiting excessive immune responses.



Dysregulated PD-L1 expression contributes to immune suppression in cancer and has been associated with chronic infections and inflammatory diseases. Therapeutically, the PD-1/PD-L1 pathway is one of the most important targets in cancer immunotherapy. Monoclonal antibodies blocking PD-1 or PD-L1 can restore antitumor T-cell activity and have demonstrated substantial clinical benefit across multiple cancers. PD-L1 is therefore both a therapeutic target and an important biomarker for patient selection in certain immunotherapy settings.

Isotype Control


PE Human IgG1 Isotype Control Antibody

Data Sheets


PE Anti-Human CD274 (PD-L1) Antibody TDS

Related Protocols


Flow Cytometry Protocol


Have a product or application question? Consult our FAQs or contact us.